After announcing plans for the filing as it reported its Q3 results last year, Pfizer’s Abrilada (adalimumab-afzb) is now one step closer to being classed as an interchangeable biosimilar with AbbVie’s Humira (adalimumab), following the US Food and Drug Administration’s acceptance for review of the prior approval supplement to the biologics license application for the compound.
The PAS was supported by positive topline data from Pfizer’s REFLECTIONS B538-12 study, which evaluated multiple switches between Abrilada and...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?